KR100848491B1 - 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법 - Google Patents

베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법 Download PDF

Info

Publication number
KR100848491B1
KR100848491B1 KR1020070004577A KR20070004577A KR100848491B1 KR 100848491 B1 KR100848491 B1 KR 100848491B1 KR 1020070004577 A KR1020070004577 A KR 1020070004577A KR 20070004577 A KR20070004577 A KR 20070004577A KR 100848491 B1 KR100848491 B1 KR 100848491B1
Authority
KR
South Korea
Prior art keywords
thiazolidine
amino
trifluorophenyl
butanoyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020070004577A
Other languages
English (en)
Korean (ko)
Inventor
김성수
천혜경
이상달
안진희
김기영
강남숙
강승규
정원훈
김성규
김선영
권재홍
손상권
신민기
하니나
Original Assignee
영진약품공업주식회사
한국화학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020070004577A priority Critical patent/KR100848491B1/ko
Application filed by 영진약품공업주식회사, 한국화학연구원 filed Critical 영진약품공업주식회사
Priority to EP08719395A priority patent/EP2118081A2/en
Priority to CA2712109A priority patent/CA2712109A1/en
Priority to JP2009546026A priority patent/JP2011509916A/ja
Priority to KR1020097017134A priority patent/KR20100094337A/ko
Priority to MX2009007630A priority patent/MX2009007630A/es
Priority to PCT/IB2008/000773 priority patent/WO2008087560A2/en
Priority to AU2008206702A priority patent/AU2008206702A1/en
Priority to CN200880007800A priority patent/CN101720319A/zh
Priority to US12/523,285 priority patent/US20100048570A1/en
Priority to BRPI0806592-6A2A priority patent/BRPI0806592A2/pt
Application granted granted Critical
Publication of KR100848491B1 publication Critical patent/KR100848491B1/ko
Priority to IL199892A priority patent/IL199892A0/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020070004577A 2007-01-16 2007-01-16 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법 Expired - Fee Related KR100848491B1 (ko)

Priority Applications (12)

Application Number Priority Date Filing Date Title
KR1020070004577A KR100848491B1 (ko) 2007-01-16 2007-01-16 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
CN200880007800A CN101720319A (zh) 2007-01-16 2008-01-16 噻唑烷衍生物及其制备方法
JP2009546026A JP2011509916A (ja) 2007-01-16 2008-01-16 チアゾリジン誘導体およびその製造方法
KR1020097017134A KR20100094337A (ko) 2007-01-16 2008-01-16 싸이아졸리딘 유도체 및 이의 제조 방법
MX2009007630A MX2009007630A (es) 2007-01-16 2008-01-16 Derivados de tiazolidina y metodos para su preparacion.
PCT/IB2008/000773 WO2008087560A2 (en) 2007-01-16 2008-01-16 Thiazolidine derivatives and methods for the preparation thereof
EP08719395A EP2118081A2 (en) 2007-01-16 2008-01-16 Thiazolidine derivatives and methods for the preparation thereof
CA2712109A CA2712109A1 (en) 2007-01-16 2008-01-16 Thiazolidine derivatives and methods for the preparation thereof
US12/523,285 US20100048570A1 (en) 2007-01-16 2008-01-16 Thiazolidine derivatives and methods for the preparation thereof
BRPI0806592-6A2A BRPI0806592A2 (pt) 2007-01-16 2008-01-16 Derivados tiazolidina e métodos para sua preparação.
AU2008206702A AU2008206702A1 (en) 2007-01-16 2008-01-16 Thiazolidine derivatives and methods for the preparation thereof
IL199892A IL199892A0 (en) 2007-01-16 2009-07-16 Thiazolidine derivatives and methods for the preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020070004577A KR100848491B1 (ko) 2007-01-16 2007-01-16 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법

Publications (1)

Publication Number Publication Date
KR100848491B1 true KR100848491B1 (ko) 2008-07-28

Family

ID=39588017

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020070004577A Expired - Fee Related KR100848491B1 (ko) 2007-01-16 2007-01-16 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
KR1020097017134A Withdrawn KR20100094337A (ko) 2007-01-16 2008-01-16 싸이아졸리딘 유도체 및 이의 제조 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020097017134A Withdrawn KR20100094337A (ko) 2007-01-16 2008-01-16 싸이아졸리딘 유도체 및 이의 제조 방법

Country Status (11)

Country Link
US (1) US20100048570A1 (enExample)
EP (1) EP2118081A2 (enExample)
JP (1) JP2011509916A (enExample)
KR (2) KR100848491B1 (enExample)
CN (1) CN101720319A (enExample)
AU (1) AU2008206702A1 (enExample)
BR (1) BRPI0806592A2 (enExample)
CA (1) CA2712109A1 (enExample)
IL (1) IL199892A0 (enExample)
MX (1) MX2009007630A (enExample)
WO (1) WO2008087560A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006214247C1 (en) 2005-02-16 2012-11-08 Anacor Pharmaceuticals, Llc Boron-containing small molecules
BRPI0621279B1 (pt) 2005-12-30 2021-07-20 Anacor Pharmaceuticals, Inc Moléculas pequenas contendo boro
CA2642583C (en) 2006-02-16 2016-08-23 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
CN102014927A (zh) 2008-03-06 2011-04-13 安纳考尔医药公司 作为抗炎药的含硼的小分子
WO2010028005A1 (en) * 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010027975A1 (en) * 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010114292A2 (ko) 2009-03-30 2010-10-07 동아제약 주식회사 디펩티딜 펩티다아제-ⅳ 저해제 및 중간체의 개량된 제조방법
SG174974A1 (en) 2009-03-30 2011-11-28 Dong A Pharm Co Ltd Improved method for preparing dipeptidyl peptidase-iv inhibitor and intermediate
AP4039A (en) 2009-08-14 2017-02-28 Daitao Chen Boron-containing small molecules as antiprotozoal agents
US9346834B2 (en) 2009-10-20 2016-05-24 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011060199A1 (en) * 2009-11-11 2011-05-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011094450A1 (en) 2010-01-27 2011-08-04 Anacor Pharmaceuticals, Inc Boron-containing small molecules
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011116348A1 (en) 2010-03-19 2011-09-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agent
AU2011237681B2 (en) * 2010-04-07 2015-01-22 Glaxosmithkline Llc Process for preparing benzoxaboroles
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
SMT202100643T1 (it) 2010-09-07 2022-01-10 Anacor Pharmaceuticals Inc Derivati del benzossaborolo per il trattamento delle infezioni batteriche
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
IN2015DN03795A (enExample) 2012-10-24 2015-10-02 Inserm Inst Nat De La Santé Et De La Rech Médicale
CN103122009B (zh) * 2013-01-09 2015-11-25 江苏吉贝尔药业股份有限公司 两种用于合成他卡西醇支链的重要中间体化合物
CN103012463B (zh) * 2013-01-17 2016-02-10 南京理工大学 (s)-3-甲基-2-(叔丁基二甲基硅氧基)-1-溴丁烷的合成方法
WO2015021396A2 (en) 2013-08-09 2015-02-12 Glaxosmithkline Intellectual Property (No.2) Limited Tricyclic benzoxaborole compounds and uses thereof
MA41495A (fr) 2015-02-12 2017-12-19 Anacor Pharmaceuticals Inc Composés benzoxaborole et leurs utilisations
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015309A1 (en) * 1993-12-03 1995-06-08 Ferring B.V. Dp-iv-serine protease inhibitors
WO1995034538A2 (en) * 1994-06-10 1995-12-21 Universitaire Instelling Antwerpen Purification of serine proteases and synthetic inhibitors thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034594A1 (en) * 1999-11-12 2001-05-17 Guilford Pharmaceuticals, Inc. Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
FR2824825B1 (fr) * 2001-05-15 2005-05-06 Servier Lab Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2003000180A2 (en) * 2001-06-20 2003-01-03 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
AU2002360732A1 (en) * 2001-12-26 2003-07-24 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
MXPA05004890A (es) * 2002-11-07 2005-07-22 Merck & Co Inc Derivados de fenilalanina como inhibidores de dipeptidilpeptidasa para el tratamiento o prevencion de diabetes.
AU2003297564A1 (en) * 2002-12-04 2004-06-23 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
AU2005293266B2 (en) * 2004-10-12 2011-09-29 Glenmark Pharmaceuticals S.A. Novel dipeptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and process for their preparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015309A1 (en) * 1993-12-03 1995-06-08 Ferring B.V. Dp-iv-serine protease inhibitors
WO1995034538A2 (en) * 1994-06-10 1995-12-21 Universitaire Instelling Antwerpen Purification of serine proteases and synthetic inhibitors thereof

Also Published As

Publication number Publication date
MX2009007630A (es) 2010-02-15
AU2008206702A1 (en) 2008-07-24
BRPI0806592A2 (pt) 2014-05-06
KR20100094337A (ko) 2010-08-26
IL199892A0 (en) 2010-04-15
WO2008087560A9 (en) 2009-07-30
CA2712109A1 (en) 2008-07-24
US20100048570A1 (en) 2010-02-25
WO2008087560A2 (en) 2008-07-24
JP2011509916A (ja) 2011-03-31
EP2118081A2 (en) 2009-11-18
WO2008087560A3 (en) 2008-09-12
CN101720319A (zh) 2010-06-02

Similar Documents

Publication Publication Date Title
KR100848491B1 (ko) 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
JP3909056B2 (ja) ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
CN107207487B (zh) 用于提高cftr活性的化合物、组合物和方法
AU717699B2 (en) Chemical compounds
ES2291966T3 (es) Inhibidores de dpp-iv.
JP4357293B2 (ja) ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
KR101344989B1 (ko) Ｐｐａｒ 작용제 활성을 갖는 유도체
US20090324581A1 (en) Heteroarylamide lower carboxylic acid derivative
WO2005058849A1 (en) New dipeptidyl peptidase in inhibitors; process for their preparation and compositions containing them
JP2010539152A (ja) 代謝障害の治療のための化合物
US8088804B2 (en) N-hydroxyamide derivatives possessing antibacterial activity
JP5493870B2 (ja) ３，８−ジアミノテトラヒドロキノリン誘導体
KR100913495B1 (ko) 베타아미노기를 갖는 1,4-디아제펜 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
KR100848490B1 (ko) 베타아미노기를 갖는 1,2,5-트리아제판 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
EP4486444A1 (en) 3-alkynyl carboxamides as aep modulators
RU2774863C2 (ru) Соединения и способы для таргетной деградации андрогенового рецептора
HK1111419A (en) Fluoropyrrolidines as dipeptidyl peptidase inhibitors

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

S14-X000 Exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S14-lic-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

S16-X000 Recordation of exclusive voluntary license cancelled

St.27 status event code: A-4-4-S10-S16-lic-X000

FPAY Annual fee payment

Payment date: 20120724

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20130723

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20140722

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

FPAY Annual fee payment

Payment date: 20150721

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20160706

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170722

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170722

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000